Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Top 5 Most-Read Oncology Articles of 2024
December 25th 2024

Top 5 Most-Read Oncology Content of 2024

Pearl Steinzor
This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!
Most Popular Articles of 2024 in Evidence-Based Oncology
December 23rd 2024

Most Popular Articles of 2024 in Evidence-Based Oncology

Mary Caffrey
Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.
Highlights From ASCO 2024
December 21st 2024

ICYMI: Highlights From ASCO 2024

Pearl Steinzor
Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.
chemotherapy | Image credit: Penn Medicine
December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey
Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
December 17th 2024

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

Pearl Steinzor
Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).
FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com
December 16th 2024

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Kristi Rosa
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
Highlights From COA 2024
December 14th 2024

ICYMI: Highlights From COA 2024

Pearl Steinzor
The Community Oncology Alliance (COA) meetings featured expert discussions around the evolving landscape of oncology care and health care reform.
AJMC
December 13th 2024

Cost-Effectiveness of a Multicancer Early Detection Test in the US

Anuraag R. Kansal, PhD Ali Tafazzoli, PhD Alissa Shaul, MPH Ameya Chavan, MS Weicheng Ye, MPH Denise Zou, MA A. Mark Fendrick, MD
Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
December 12th 2024

Improving Access to Nivolumab by Lowering Age Restrictions in Clinical Trial

Pearl Steinzor
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, member of the Lymphoma Research Foundation’s Scientific Advisory Board, shares findings on innovative strategies to improve access to new therapies in pediatric cancer.
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health
December 10th 2024

How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL

Pearl Steinzor
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).
Person fills prior authorization form - Maksim Shchur - stock.adobe.com.jpeg
December 4th 2024

Prior Authorization Delays Cause Serious Harm to Patients With Cancer

Pearl Steinzor
Insurance hurdles worsen delays, force abandoned treatments, and result in hospitalizations and deaths, radiation oncologists report nationwide.
Highlights From ACCC Annual Meeting & Cancer Center Business Summit
December 4th 2024

ICYMI: Highlights From ACCC Spring 2024

Pearl Steinzor
Our top content from the Spring Association of Cancer Care Centers (ACCC) Annual Meeting & Cancer Center Business Summit featured topics on health care worker retention, advancements in precision medicine, and more!
Sandra Cuellar, PharmD
November 29th 2024

From Data to Dialogue: Transforming Oncology With Real-World Evidence

Skylar Jeremias
Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.
FDA approval. | Image Credit: syahrir - stock.adobe.com
November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro
Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.
Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com
November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser
Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).
Kasey Bond, MPH, Perlmutter Cancer Center
November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Maggie L. Shaw
Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
FDA Approval-BHM-stock.adobe.com
November 14th 2024

FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions

Giuliana Grossi
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Oscar B. Lahoud, MD, NYU Langone Health
November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

Maggie L. Shaw
In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
AJMC
November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH
Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
doc reviewing lung report | Image Credit: © meeboonstudio - stock.adobe.com
November 8th 2024

Research Reveals Common Types of Rituximab-Induced Interstitial Lung Disease in Patients With Lymphoma

Karen Jacobson-Sive
Rituximab-induced interstitial lung disease in patients with non-Hodgkin lymphoma presents with distinct clinical characteristics and bronchoalveolar lavage results.
Karen Winkfield, MD, PhD
November 7th 2024

Adapting Cancer Treatment for Survivorship and Precision Care

Maggie L. Shaw
The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”
Fish oil supplements in fish shape | Image credit: zilvergolf – stock.adobe.com
November 5th 2024

High Omega-3, Omega-6 Levels May Lower Cancer Risk

Hayden E. Klein
Higher levels of these fatty acids may reduce the risk of developing several types of cancer, though certain risks, such as a potential link to prostate cancer, highlight the complexity of their impact on overall cancer risk.
Cancer disparities | Image credit: Yurii Kibalnik - stock.adobe.com
November 4th 2024

Disparities in Cancer Mortality Among Asian Americans and Pacific Islanders

Pearl Steinzor
Despite an overall decline in cancer-specific mortality, death rates from certain cancer types are rising among Asian American and Pacific Islander populations.
Smoking | Image credit: ehabeljean - stock.adobe.com.jpg
October 31st 2024

Early Smoking Cessation Treatment After Cancer Diagnosis Improves Survival

Pearl Steinzor
Smoking after a cancer diagnosis increases risk of mortality and a second cancer, study finds.
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
October 28th 2024

Transforming Oncology Care With AI-Driven Insights

Pearl Steinzor
Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.
Vinayak Venkataraman, MD
October 24th 2024

Sarcoma Care: Biomarker Advancements Shape the Future

Maggie L. Shaw
At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Gut health concept | Image credit: faithie - stock.adobe.com
October 23rd 2024

Ixcela, Roper St. Francis Healthcare Launch Innovative Cancer Support Program to Improve Treatment Outcomes

Pearl Steinzor
A pioneering program targeting gut microbiome health significantly reduces cancer treatment side effects, enhancing patient well-being and resilience.
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
October 21st 2024

Bridging the Digital Divide of Rural Cancer Care With Telehealth

Cameron Santoro
Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.
Hari Deshpande, MD, Yale Cancer Center
October 17th 2024

Elevating Sarcoma Outcomes Through Value-Based Care

Maggie L. Shaw
At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.
Advancing health equity can be achieved through community engagement | image credit: Andrii - stock.adobe.com
October 16th 2024

Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity

Kyle Munz
Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
<123456789
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo